Managed Care Considerations for a First-in-Class M1/M4 Muscarinic Agonist for the Treatment of Adults With Schizophrenia
Advertisement
Advertisement
Trending on AJMC
1
NIH Grant Terminations Disrupt 1 in 30 Clinical Trials, Impacting Over 74,000 Participants
2
How Effective and Safe Are GLP-1s for Weight Loss?
3
FDA Approves Plozasiran to Reduce Triglycerides in Familial Chylomicronemia Syndrome
4
Rescue Therapy With Rozanolixizumab Promising in Triple-Seronegative MG
5
